Summit Therapeutics Inc
For the period ended Mar 31, 2025. Filed May 1, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 1, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Subsequent Events.
On April 29, 2025, the Compensation Committee and the Board approved a modification to certain named executive officer’s outstanding unvested performance-based stock option awards issued under the Company’s 2020 Stock Incentive Plan that will require only the service-based vesting requirements to continue to be satisfied in order to become fully vested, subject to each of Mahkam Zanganeh’s and Manmeet Soni’s consent. Dr. Mahkam Zanganeh and Mr. Manmeet Soni consented to the modification, whereby 50% of their outstanding unvested performance-based stock options vested on April 29, 2025 and the remaining 5.5 million and 5.6 million, respectively, vest in three annual tranches beginning October 2025.
10b5-1 Trading Plans.
None.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.